YourEncore Insights - Life Sciences

Drug Pricing – What’s the Answer to High Cost Off-Patent Medicines?

Posted by Jim Combs on 9/13/16 11:00 AM

In the wake of the Turing, Valeant, and Mylan EpiPen pricing controversies, YourEncore Insights coordinated a conversation with two top experts to discuss potential solutions to some drug pricing dilemmas.  I interviewed Peter J. Pitts, former FDA Associate Commissioner and President of the Center for Medicine in the Public Interest, and Dr. Tim Franson, YourEncore’s Chief Medical Officer and former VP of Global Regulatory Affairs for Eli Lilly and Company.

The transcript is provided below: 

Read More

Topics: Pharmaceutical Industry, FDA, Drug Pricing